Halozyme Therapeutics Inc HALO
News
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
Halozyme to Present at Upcoming Investor Conferences
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme to Report Second Quarter 2024 Financial and Operating Results
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation